News
Article
Symbiosis Pharmaceutical Services Completes Successful Sterile Inspection
Author(s):
The company’s Scotland-based facility has successfully completed a scheduled inspection by the UK’s MHRA; there were no critical or major observations noted.
Symbiosis Pharmaceutical Services, a CMO in parenteral manufacturing, announced that its Scotland-based facility has successfully completed a scheduled inspection by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). There were no critical or major observations noted.
Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products for clinical trials. The company has received confirmation of continued authorization for the GMP manufacture of aseptically-filled licensed commercial products following initial approval of the commercial manufacturer’s/importers license in 2014.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
